Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.36 |
| ▸ | CTSD | P07339 | 2/20 | 0.35 |
| ▸ | CTSL | P07711 | 2/20 | 0.35 |
| ▸ | CTSB | P07858 | 2/20 | 0.35 |
| ▸ | CTSS | P25774 | 2/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14990254 | 0.90 | RECQL (0.33) | USP2SMN1; SMN2RECQLPIK3CDCTSD | |
| SCHEMBL14853377 | 0.90 | RECQL (0.33) | USP2SMN1; SMN2RECQLPIK3CDCTSD | |
| SCHEMBL4367475 | 0.87 | CHRM2 (0.34) | GPR119HSD11B1CHRM2CHRM1CHRM3 | |
| SCHEMBL9964560 | 0.85 | BTK (0.37) | GPR119HSD11B1CHRM2CHRM1CHRM3 | |
| SCHEMBL574102 | 0.84 | BTK (0.36) | HSD11B1CHRM2CHRM1CHRM3 | |
| SCHEMBL14853126 | 0.83 | USP2 (0.39) | USP2SMN1; SMN2RECQLCTSDCTSL | |
| SCHEMBL871258 | 0.82 | GAA (0.37) | CTSSHSD11B1CHRM2CHRM1CHRM3 | |
| SCHEMBL224478 | 0.81 | HSD11B1 (0.42) | USP2SMN1; SMN2RECQLPIK3CDCTSD | |
| SCHEMBL15021681 | 0.79 | SLC6A4 (0.32) | HSD11B1CHRM2CHRM1CHRM3 | |
| SCHEMBL22519341 | 0.79 | USP2 (0.39) | USP2SMN1; SMN2RECQLPIK3CDCTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118401516-A | TYK2 inhibitors, compositions and methods thereof | 凌科药业(杭州)有限公司 | 2024-07-26 | — | — | CN | disclosed |
| US-20110118208-A1 | Thiazolyl-Dihydro-Indazoles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118208-A1 | Thiazolyl-Dihydro-Indazoles | MKI67, CYP11B1, IGF1R | USP2 4682/4885SMN1; SMN2 1428/4885RECQL 1768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.